DCM
ARIA

DAFNA Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

DAFNA Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-148,915
Closed -$2.74M – 54
2013
Q3 		$2.74M Sell
148,915
-42,300
-22% -$821K 2.99% 13
2013
Q2 		$3.34M Buy
+191,215
New +$3.39M 4.89% 8

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

DAFNA Capital Management's ARIA Position: Q4 2013 in Review

DAFNA Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2013, closing a stake of 148,915 shares — an estimated $2.74M sold.

DAFNA Capital Management first reported a position in ARIA in Q2 2013 and held it in 2 quarters. The position peaked at $3.34M in Q2 2013. 166 funds tracked by Wall St. Rank hold ARIA as of Q4 2013.

  • DAFNA Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • DAFNA Capital Management sold 148,915 Ariad Pharmaceuticals Inc shares in Q4 2013, an estimated $2.74M.
  • DAFNA Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • DAFNA Capital Management's Ariad Pharmaceuticals Inc position peaked at $3.34M in Q2 2013.
  • 166 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2013.

Based on DAFNA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.